✦ LIBER ✦

Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT

✍ Scribed by Pitini, V; Arrigo, C; Aloi, G; Micali, C; La Gattuta, G

Book ID: 110013764
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 64 KB
Volume: 31
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bmt.1704079

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thalidomide, dexamethasone and lovastati

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma

✍ Marek Hus; Norbert Grzasko; Marta Szostek; Andrzej Pluta; Grzegorz Helbig; Dariu 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 218 KB

Response to single-agent thalidomide and

Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD

✍ Milone, J H; Prates, V; Bordone, J; Napal, J; Garcia, C 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 59 KB

Salvage autologous or allogeneic transpl

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

✍ Singhal, S; Siegel, D; Desikan, K; Munshi, N; Fassas, A; Mattox, S; Mehta, J; Tr 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 58 KB

Bortezomib, doxorubicin, and dexamethaso

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

✍ Sung Sook Lee; Cheolwon Suh; Bong-Seog Kim; Jooseop Chung; Young-Don Joo; Hun-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 151 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Effectiveness and safety of high-dose cy

Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents

✍ Guillermo L. Rivell; Chris Y. Brunson; Laura Milligan; Robert K. Stuart; Luciano 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 681 KB